Strong clinical progress in AML and CNS programs, with iadademstat showing high response rates and vafidemstat advancing toward Phase III in BPD. Financial position strengthened by a €12M capital raise and a €25M future investment commitment from COFIDES.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.